Author: PharmaSignal News Desk

Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.

Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.

Novo Nordisk GLP-1 trials did not meet primary endpoints in Alzheimer’s studies, impacting potential neurodegeneration treatment.

J&J Alzheimer’s trial failure with posdinemab dims hopes for new treatments.

Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.

Novo Nordisk Alzheimer’s trial with semaglutide fails to slow disease progression in over 3,800 patients.

Takeda rare disease drug is under FDA investigation following a patient death and reports of neutralizing antibodies.

Biogen Dayra partnership aims to identify oral macrocycle candidates for high-priority immunological targets, enhancing Biogen’s immune portfolio.

QurAlis hires Manoj Malhotra as Chief Medical Officer, leveraging his experience from AbbVie to strengthen its leadership.

FDA priority voucher drug vote excluded review staff, involving top officials in a major procedural shift.